,38 Our study found that CR108, an adjuvant, enhanced the ability of skin-derived KikGR-red cells to cross-present antigens, priming CD8+ T cells and generating cytotoxic effector cells crucial for tumor elimination. The gene discussed is CD8A; the disease is neoplasm.